Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 6 studies | 26% ± 12% | |
brain | 6 studies | 30% ± 9% | |
peripheral blood | 5 studies | 33% ± 10% | |
eye | 5 studies | 21% ± 5% | |
pancreas | 3 studies | 32% ± 17% | |
bone marrow | 3 studies | 17% ± 2% | |
intestine | 3 studies | 22% ± 7% | |
liver | 3 studies | 31% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 3314.41 | 2642 / 2642 | 100% | 34.95 | 705 / 705 |
esophagus | 100% | 3876.67 | 1445 / 1445 | 100% | 26.26 | 183 / 183 |
ovary | 100% | 2927.91 | 180 / 180 | 100% | 20.46 | 430 / 430 |
prostate | 100% | 2849.56 | 245 / 245 | 100% | 21.82 | 502 / 502 |
uterus | 100% | 3485.84 | 170 / 170 | 100% | 28.07 | 459 / 459 |
lung | 100% | 3158.11 | 578 / 578 | 100% | 24.03 | 1153 / 1155 |
breast | 100% | 3195.79 | 459 / 459 | 100% | 25.83 | 1116 / 1118 |
bladder | 100% | 3186.24 | 21 / 21 | 100% | 24.65 | 503 / 504 |
kidney | 100% | 2945.44 | 89 / 89 | 100% | 19.28 | 899 / 901 |
pancreas | 100% | 2045.72 | 327 / 328 | 100% | 21.40 | 178 / 178 |
thymus | 100% | 3269.37 | 653 / 653 | 100% | 28.62 | 603 / 605 |
intestine | 100% | 3721.54 | 966 / 966 | 100% | 24.66 | 525 / 527 |
stomach | 100% | 2682.95 | 359 / 359 | 99% | 23.61 | 284 / 286 |
adrenal gland | 100% | 2895.71 | 258 / 258 | 99% | 21.06 | 227 / 230 |
skin | 100% | 3767.42 | 1809 / 1809 | 97% | 21.44 | 457 / 472 |
liver | 97% | 1148.96 | 220 / 226 | 97% | 12.22 | 394 / 406 |
adipose | 100% | 3153.31 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4312.94 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 25.37 | 29 / 29 |
muscle | 100% | 2981.51 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3242.29 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 22.73 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 13.98 | 1 / 1 |
heart | 97% | 1854.58 | 833 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 95% | 2193.36 | 880 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 93% | 13.27 | 74 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0030071 | Biological process | regulation of mitotic metaphase/anaphase transition |
GO_0045582 | Biological process | positive regulation of T cell differentiation |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_2000045 | Biological process | regulation of G1/S transition of mitotic cell cycle |
GO_0045663 | Biological process | positive regulation of myoblast differentiation |
GO_0006338 | Biological process | chromatin remodeling |
GO_0070316 | Biological process | regulation of G0 to G1 transition |
GO_0045597 | Biological process | positive regulation of cell differentiation |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0007346 | Biological process | regulation of mitotic cell cycle |
GO_2000819 | Biological process | regulation of nucleotide-excision repair |
GO_2000134 | Biological process | negative regulation of G1/S transition of mitotic cell cycle |
GO_0016055 | Biological process | Wnt signaling pathway |
GO_2000781 | Biological process | positive regulation of double-strand break repair |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0045815 | Biological process | transcription initiation-coupled chromatin remodeling |
GO_0000776 | Cellular component | kinetochore |
GO_0005654 | Cellular component | nucleoplasm |
GO_0016363 | Cellular component | nuclear matrix |
GO_0016586 | Cellular component | RSC-type complex |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0042393 | Molecular function | histone binding |
GO_0000976 | Molecular function | transcription cis-regulatory region binding |
GO_0070577 | Molecular function | lysine-acetylated histone binding |
GO_0003714 | Molecular function | transcription corepressor activity |
GO_0002039 | Molecular function | p53 binding |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | BRD7 |
Protein name | Bromodomain containing 7 Bromodomain-containing protein 7 (75 kDa bromodomain protein) (Protein CELTIX-1) |
Synonyms | CELTIX1 BP75 |
Description | FUNCTION: Acts both as coactivator and as corepressor. May play a role in chromatin remodeling. Activator of the Wnt signaling pathway in a DVL1-dependent manner by negatively regulating the GSK3B phosphotransferase activity. Induces dephosphorylation of GSK3B at 'Tyr-216'. Down-regulates TRIM24-mediated activation of transcriptional activation by AR (By similarity). Transcriptional corepressor that down-regulates the expression of target genes. Binds to target promoters, leading to increased histone H3 acetylation at 'Lys-9' (H3K9ac). Binds to the ESR1 promoter. Recruits BRCA1 and POU2F1 to the ESR1 promoter. Coactivator for TP53-mediated activation of transcription of a set of target genes. Required for TP53-mediated cell-cycle arrest in response to oncogene activation. Promotes acetylation of TP53 at 'Lys-382', and thereby promotes efficient recruitment of TP53 to target promoters. Inhibits cell cycle progression from G1 to S phase. . |
Accessions | ENST00000394688.8 [Q9NPI1-1] ENST00000710357.1 A0AA34QW01 ENST00000569774.6 A0AA34QVS2 ENST00000562383.6 Q9NPI1 I3L0Y7 I3L4V5 ENST00000710356.1 ENST00000394689.2 [Q9NPI1-2] |